A growing number of optogenetic tools have been developed to control binding between two engineered protein domains. In contrast, relatively few tools confer light-switchable binding to a generic target protein of interest. Such a capability would offer substantial advantages, enabling photoswitchable binding to endogenous target proteins in vivo or light-based protein purification in vitro. Here, we report the development of opto-nanobodies (OptoNBs), a versatile class of chimeric photoswitchable proteins whose binding to proteins of interest can be enhanced or inhibited upon blue light illumination. We find that OptoNBs are suitable for a range of applications: modulating intracellular protein localization and signaling pathway activity and controlling target protein binding to surfaces and in protein separation columns. This work represents a first step towards programmable photoswitchable regulation of untagged, endogenous target proteins. Highlights 1. Opto-Nanobodies (OptoNBs) enable light-regulated binding to a wide range of protein targets. 2. We identify an optimized LOV domain and two loop insertion sites for light-regulated binding. 3. OptoNBs function in vivo: when expressed in cells and fused to signaling domains, OptoNBs enable light-activated and light-inhibited Ras/Erk signaling. 4. OptoNBs function in vitro: Target proteins can be reversibly bound to OptoNB-coated beads and separated through size-exclusion chromatography.
Abstract
A growing number of optogenetic tools have been developed to control binding between two engineered protein domains. In contrast, relatively few tools confer light-switchable binding to a generic target protein of interest. Such a capability would offer substantial advantages, enabling photoswitchable binding to endogenous target proteins in vivo or light-based protein purification in vitro. Here, we report the development of opto-nanobodies (OptoNBs), a versatile class of chimeric photoswitchable proteins whose binding to proteins of interest can be enhanced or inhibited upon blue light illumination. We find that OptoNBs are suitable for a range of applications: modulating intracellular protein localization and signaling pathway activity and controlling target protein binding to surfaces and in protein separation columns. This work represents a first step towards programmable photoswitchable regulation of untagged, endogenous target proteins.
Introduction
Nearly 20 years after the initial development of light-regulated transcription in yeast 1 and light-gated ion channels in neuroscience 2 , optogenetics has been extended to almost every corner of cell biology. Optogenetic proteins are now available to control the fundamental currencies of protein heterodimerization [3] [4] [5] , homo-dimerization 6, 7 , gene expression 1, 8, 9 , degradation 10 , nuclearcytosolic translocation [11] [12] [13] [14] , and even liquid-liquid protein phase separation 15, 16 . These techniques have enabled a new generation of precise perturbation studies to interrogate how the timing, spatial location, and identity of active proteins alter cellular and developmental processes.
Yet despite this growing suite of optogenetic tools, some applications have remained elusive.
Light-gated protein-protein interactions are typically induced between a light-sensitive protein and a target peptide that is derived from the original plant or cyanobacterial host (e.g., dimerization between PhyB/PIF6 or Cry2/CIB) 3, 5, 6 , or an engineered, synthetic protein-protein interaction (e.g., binding of an engineered AsLOV2 variant to a PDZ or SSPB peptide or between Dronpa monomers) 4, 7, 17 . In contrast, achieving light-switchable binding to an arbitrary target protein of interest has remained elusive. The ability to reversibly bind and release a protein of interest in response to light would hold considerable promise for reversibly regulating endogenous signaling activity in vivo, developing biologics that can be precisely targeted in space and time, and enabling protein purification without affinity tags.
Here, we present opto-nanobodies (OptoNBs): a class of engineered proteins capable of reversible, light-controlled binding against multiple protein targets. Nanobodies, small binding proteins formed from the single variable domain of camelid antibodies, provide a versatile scaffold for obtaining binding to a broad range of target epitopes and are functional in both intracellular and extracellular environments 18 . Our approach for obtaining photoswitchable nanobodies builds on recent pioneering work to insert a photoswitchable light-oxygen-voltage (LOV) domain into solvent-exposed loops on proteins of interest 19 . We identify loop insertion sites and LOV domain variants that trigger a light-inducible change in binding in three nanobodies against two model target proteins, EGFP and mCherry. We further demonstrate that nanobody binding can be applied in vivo and in vitro, in applications ranging from control over mammalian Ras/Erk signaling to photoswitchable binding on agarose beads and in size exclusion columns. The OptoNB platform opens the door to developing light-switchable binders against a broad range of protein targets and may thus represent a first step toward a new class of photoswitchable biologics.
Results

Initial optoNBs exhibit weak light-switchable binding as well as nuclear export
Our strategy to engineer light-controlled nanobodies is based on pioneering work using ligand-or light-gated 'hairpins': small domains that can be inserted in-frame into a solventexposed loop, whose conformation changes upon illumination or addition of a small molecule 19, 20 . We reasoned that by inserting a light-oxygen-voltage sensing domain from Avena sativa Phototropin 1 (AsLOV2) into the solvent-exposed loop of a nanobody, it may be possible to allosterically alter the conformation of its binding surface, disrupting recognition of a target protein ( Figure 1A) . As a starting point, we focused on regulating binding between a model target protein, mCherry, and the LaM8 anti-mCherry nanobody 21 . We took a broad approach to identifying potential AsLOV2 insertion sites, testing all eight conserved, solvent-exposed loops in the nanobody structure excluding the hypervariable complementarity determining regions (CDRs) (Figure 1B, arrows) .
We first set out to establish a cell-based assay for evaluating whether candidate optonanobodies exhibited light-switchable binding. Prior work has shown that monitoring cytosol-tomembrane translocation is a fast and sensitive method to characterize light-switchable binding ( Figure 1A) , revealing changes in protein localization for a diverse set of heterodimerization pairs and affinities 3, 5, 17 . We thus generated a set of HEK293 cell lines expressing a membranetagged mCherry target protein (mCherry-CAAX) and one of 10 candidate OptoNBs that were each fused on their C-terminus to an infrared fluorescent protein (OptoNB-irFP) ( Figure 1A, lower panel, and 1C). We then imaged each cell line to determine the OptoNB's subcellular localization in the presence or absence of 450 nm blue light.
The initial screen yielded diverse results for different nanobody-LOV fusions. Crucially, we observed redistribution between cytosol and membrane for two OptoNB fusions: those targeting the "GG15" and "AK74" insertion sites on Loops 1 and 6 of the nanobody (Figure 1B , green and purple arrows). (We name insertion sites based on the nanobody's flanking amino acids and the position number of insertion, so AK74 corresponds to the sequence …-Ala-AsLOV2-Lys-… with AsLOV2 inserted after Ala74.) We found that light stimulation of these two sites triggered opposite effects on nanobody-mCherry binding: light-induced dissociation in the case of GG15 and binding in the case of AK74 (Figure 1D-E) . This set of chimeras with opposite response to light was surprising, as prior studies that took advantage of LOV insertion reported only lightinduced disruption of protein function, which was explained by the increased flexibility of the By insertion into a solvent-exposed turn or loop, the light-switchable AsLOV2 domain (blue) could modulate the conformation of a nanobody (gray), thus allosterically altering its ability to bind to a target protein (red). Cytosolic irFP-fused OptoNBs were assayed for translocation to membrane-bound mCherry in the presence or absence of blue light. (B) Crystal structure of the LaG4 nanobody (blue) bound to EGFP (green), (PDB:3OGO), indicating loops targeted for LOV domain insertion (arrows). Two loops are highlighted containing Ala74 (green arrow) and Gly15 (purple arrow). (C) Results for insertion at 1-2 sites in all 8 loops. HEK293 cells expressing membrane-tethered mCherry (mCherry-CAAX) and light-stimulated state disrupting the fusion protein's active state 19, 22 . In contrast, our data on the AK74 chimera suggests that the AsLOV2 dark state can also disrupt function, which is restored upon blue light illumination. We constructed a second round of cell lines to test additional insertion sites in Loops 1 and 6 where we obtained hits (positions 15-17 and 72-77) (Figures S1A). We observed similar light-induced changes at one additional site within each loop (GS16 and DN72), demonstrating that multiple sites within a single loop can be used to achieve photoswitchable binding control ( Figure S1B) .
Our initial results demonstrate that LOV-nanobody chimeric proteins are indeed capable of photoswitchable binding. They also reveal two distinct classes of optoNBs, those for which binding occurs in the light and others for which it occurs in the dark. The ability to induce binding by switching to dark conditions is rare, as most previously-developed optogenetic tools exhibit light-induced binding; yet the few existing light-suppressible optogenetic tools available 23, 24 have already proven useful for probing T cell signaling 25 , controlling metabolic flux 26, 27 , and studying the consequences of protein phase separation 15 . Photoswitchable domain insertion thus holds promise for engineering light-based control of protein-protein interactions.
An optimized LOV domain improves OptoNB function
Our initial screen also revealed that, for some optoNBs (GG15, NA73, and MG77), light unexpectedly triggered nuclear export (Figure S1C-D). Nuclear export observed even in cells that did not express membrane mCherry; furthermore, it was quickly reversed in the dark for the GG15 and MG77 variants but was irreversible for the NA73 variant. We thus next set out to improve the performance of our initial OptoNBs in two ways: eliminating undesired nuclear-cytosolic translocation of the nanobody and achieving a larger change in binding between dark and illuminated conditions. We hypothesized that the light-induced nuclear/cytosolic translocation might arise due to light-triggered exposure of a nuclear export sequence (NES), as has been engineered in prior AsLOV2-based optogenetic tools 12, 14 . Indeed, amino acid sequence analysis revealed a canonical NES (LxxxLxxLxL, where x is any amino acid and L is a hydrophobic amino acid that is often leucine) spanning the junction between the C-terminal Jα helix and nanobody for the GG15 and MG77 insertion sites ( Figure S1E ). (We did not observe a canonical NES for the NA73 variant, suggesting a different mechanism underlies its irreversible nuclear export.) We thus sought to truncate residues from the nanobody's C-terminus to eliminate undesired NES activity. We also reasoned that truncating amino acids from the nanobody-AsLOV2 junction may have an additional benefit, enabling tighter conformational coupling between the LOV domain and nanobody. A close examination of the crystal structure of AsLOV2 (PDB: 2V0U) suggested that removing linker residues at both the N and C termini of the AsLOV2 domain could more tightly couple it to the nanobody (Figure 2A) .
Based on this rationale, we constructed a 'short LOV' (sLOV) domain, comprising residues 408-543 of Avena sativa Phototropin 1 (versus residues 404-546 in Figure 1 
OptoNBs can be constructed for multiple nanobodies and target proteins
Our initial OptoNB designs were in the context of a single binding pair: the LaM8 nanobody and its mCherry binding partner. We next sought to test whether light-induced binding or dissociation generalizes to other nanobodies or targets. Alignment of multiple nanobody sequences (our original LaM8 nanobody, the higher-affinity mCherry nanobody LaM4, and an anti-EGFP nanobody LaG9) indicates that both the AK74 and GG15 insertion sites are located in conserved regions that are distinct from the hypervariable complementarity-determining regions (CDRs) ( Figure 3A ) 21 . We thus hypothesized that similar effects would be elicited upon LOV domain insertion in the same sites of each nanobody.
We generated sLOV insertions at the GG15 and AK74 positions in LaM4-irFP and LaG9-irFP fusion proteins. We then co-transduced cells with membrane mCherry or EGFP and monitored cytosolic OptoNB levels during cycles of blue light illumination or darkness ( Figure   3B ). We found that insertion at the GG15 position led to consistent light-inducible dissociation in all three nanobodies, although both LaM4 and LaG9 exhibited weaker dissociation than LaM8, possibly due to their higher-affinity target binding (0.18 and 3.5 nM, respectively, vs. 63 nM for LaM8) 21 . In contrast, AK74 insertion led to highly variable results across all three nanobodies: we observed light-induced binding in the cases of LaM8 and LaG9, but lighttriggered dissociation for LaM4. Our results thus indicate that sLOV insertion at the same sites (GG15 and AK74) confers light-regulated target binding across multiple nanobodies (LaM8, LaM4, LaG9) and/or target proteins (GFP, mCherry). Insertion at the GG15 position appears to generally elicit light-triggered dissociation, whereas AK74 insertion appears to be more variable, with changes in both the sign and magnitude of photoswitchable binding observed between distinct nanobodies. This result is consistent with a model where light-induced destabilization of LOV domain contacts are more likely to disrupt protein function upon light stimulation than to restore it 19 , suggesting that the light-induced binding we observed in LaM8-AK74 may be a relatively unusual occurrence. 
Coupling OptoNBs to Ras/Erk signaling in vivo
Because our initial screen demonstrated light-directed control over protein binding in live mammalian cells, we reasoned that it should thus be possible to apply OptoNBs for light-based control over cellular functions without any further modification or optimization. To demonstrate this capability, we set out to construct an OptoNB-based variant of the OptoSOS optogenetic tool 28 Figure 3D) . These results demonstrate that OptoNBs can indeed be deployed in cells to manipulate downstream cellular functions (e.g., Ras/Erk signaling) without further optimization.
OptoNBs regulate protein binding in vitro
In addition to controlling intracellular protein-protein interactions, light-controlled nanobodies could be useful in vitro for a variety of applications, including extracellular reagents to modulate receptor-level responses 31 , and the ability to decorate light-switchable binders in biochemical purification columns to separate unmodified target proteins based on light stimuli 32 .
We thus set out to characterize the light-dependent performance of OptoNBs in vitro in a variety of assays: column-based separation, protein binding to OptoNB-coated agarose beads, and biolayer interferometry-based measurement of OptoNB-protein binding kinetics.
As a first test of their function in vitro, we sought to test whether purified OptoNBs and their binding partners could be differentially separated in light and darkness using size exclusion chromatography. We expressed and purified the dark-inducible binder LaM4-TK74 and the light-inducible binder LaM8-AK74 from E. coli (see Supplementary Methods) . We wrapped a Superdex 200 10/300 GE column with blue light-emitting diodes (LEDs; Figure 4A ) or wrapped it in aluminum foil (to keep dark conditions), and flowed solutions containing OptoNB, mCherry, or both in a 1:1.2 molar ratio of NB to mCherry through the column (Figure 4B-C) .
We observed a strong light-dependent shift in retention time for both OptoNBs. In the case of LaM8-AK74, light-induced binding leads to a shorter retention time under illumination ( Figure   4B , blue curve), and a longer complex retention time as well as a peak of free mCherry in the dark (Figure 4B , black curve; compare to red curve for free mCherry). LaM4-TK74 exhibits the converse response, with shorter retention in the dark and longer in the light, indicating lightinduced dissociation as previously observed in vivo (Figure 4C) . Many in vitro and extracellular applications of protein binders are based on interactions on surfaces (e.g., cell surface receptor binding; affinity-based purification using bead-tethered antibodies). We thus sought to test whether OptoNB-target interactions could be controlled on the surface of agarose beads (Figure 4D) . We purified His-tagged OptoNBs (His6-LaM8-AK74
and His6-LaM8-GG15), as well as His6-GFP and His6-mCherry from E. coli (see Supplementary Methods). To obtain beads with different surface densities of immobilized OptoNBs, we incubated nickel-NTA-coated agarose beads with solutions containing different ratios of anti-mCherry His6-OptoNB and His6-GFP (where His6-GFP was used as a bead surface blocking agent) to achieve different surface densities of OptoNBs.
To test for light-dependent mCherry binding, we incubated the OptoNB-labeled beads with soluble mCherry (His6-cleaved) and imaged mCherry fluorescence during cycles of blue light illumination (Figure 4E-F; Movies S5-6 ). We observed a light-dependent shift in surface mCherry fluorescence as expected for AK74-and GG15-based OptoNBs. However, the time required to saturate the beads with bound nanobody upon light activation depended strongly on the density of target protein on the beads (Figure S2) . Complete mCherry binding was achieved within 10 sec when beads were labeled with a 0.5%:99.5% LaM8-AK74:GFP protein ratio. In contrast, beads labeled with 100% LaM8-AK74 were only gradually saturated with mCherry over ~1 h. This phenomenon is likely due to local depletion of mCherry near the illuminated (blue shading indicates LED illumination). Bottom panels: quantification of bead surface intensity during cycles of darkness and blue light illumination. (G) Representative bio-layer interferometry (BLI) traces for quantifying nanobody-protein binding and dissociation kinetics. Four phases indicate His-tagged OptoNB loading onto the Ni-NTA coated tips, equilibration in buffer, binding to different concentrations of soluble mCherry, and mCherry dissociation into buffer. (H) Raw data (solid lines) and best-fit traces simultaneously fit to simple mass-action kinetic binding model (dashed lines) for the Ni-NTA sensorimmobilized LaM8 nanobody binding to soluble mCherry at eight concentrations. bead's surface at high labeling densities, a picture that is consistent with the approximately linear increase in surface mCherry observed at high OptoNB concentrations 33 . In sum, we find that OptoNBs exhibit light-switchable binding to their targets across a broad range of contexts, from the mammalian intracellular environment to surface-and solution-based binding in vitro.
Measurement of lit-and dark-state OptoNB binding kinetics
As a final characterization of OptoNB activity, we set out to perform quantitative measurements of their binding affinity and kinetics in the lit and dark states using bio-layer interferometry (BLI). We reasoned that BLI would be ideal for quantifying light-triggered protein-protein interactions due to its compatibility with sample illumination and accurate quantification of both binding kinetics and affinity. Binding measurements in the dark state can be made by taking advantage of the C450V point mutation in AsLOV2 which prevents photoadduct formation, rendering AsLOV2-based optogenetic tools light-insensitive 34, 35 .
Although a variety of lit state mutants have been characterized that destabilize docking of the Cterminal Jα and N-terminal A'α helices 36, 37 , it is unclear whether these mutations fully mimic the lit state when these helices are constrained by being inserted into loops of a chimeric fusion, as in our OptoNBs.
We first expressed and purified His-tagged variants of the parental LaM8 nanobody, the LaM8-AK74 and LaM8-GG15 OptoNBs, and OptoNB mutants that are expected to be lightinsensitive and locked in either the dark state (C450V equivalent) or lit state (I532E A536E equivalents) 38 . For each BLI run, one of these nanobody variants was loaded onto Ni-NTAcoated sensors, equilibrated in buffer, exposed to varying concentrations of mCherry to measure the association phase, and finally washed to measure the dissociation phase (Figure 4G) . The binding curves at all mCherry concentrations were then globally fit to a simple mass-action chemical kinetic model of binding and dissociation, from which estimates of kon, koff, and KD were obtained (Figure 4H, Supplementary Code) . The global fitting procedure was able to fit the data well in each case (Figure S3) . The resulting kinetics and affinities are presented in Table 1 . We measured an affinity of 230 nM for wild-type LaM8, which differed somewhat from the 63 nM affinity reported previously 21 , possibly due to differences in assay design and procedures used to fit binding curves. We found that the LaM8-GG15 OptoNB also exhibited sub-micromolar affinity for mCherry in its dark state (610 nM) that was weakened to 1.7-2.4 μM in the lit state. In contrast, the LaM8-AK74 variant exhibited weaker affinity for mCherry in its dark state (19.9 μM) than its lit state (3.65-3.79 μM), just as we had observed in vivo and in vitro. All lit state measurements agreed closely between illuminated, photosensitive OptoNBs and lit-state mutants, suggesting that these mutants accurately reflect the nanobody's lit state. Finally, we note that in each case, the affinity 
Variant Illumination kon (μM -1 s -1 ) koff (s -1 ) KD (μM)
Discussion
Here we have shown that a simple strategy for constructing light-sensitive proteins -the insertion of a photoswitchable domain into a target protein -can be used to produce lightsensitive nanobodies (OptoNBs). Nanobodies are a class of proteins with high potential as biological reagents for cell and developmental biology 39, 40 , biotechnology 32 , and therapeutic applications 31, 41 because of their small size, ease of expression and purification in both bacterial and eukaryotic cells, and high-affinity binding to a growing list of target proteins. We show that
OptoNBs can be produced from multiple nanobody scaffolds, show activity against multiple target proteins, can exhibit either light-inducible or light-dissociable responses, and can be functionally coupled to cell signaling in vivo and column-based assays in vitro. We further describe design variants to optimize OptoNB function, including an optimized, shortened
AsLOV2 scaffold that improves photoswitchable binding in 5 of the 6 cases tested and eliminates a side pathway -light-switchable nuclear export -that could be relevant for intracellular applications.
The ability to control nanobody binding with light offers considerable promise for a variety of applications. Nanobodies can be raised against a broad range of target peptides through affinity maturation in immunized camelids, making it easy to envision proteins whose binding can be toggled on and off from a broad range of endogenous protein targets. In many cases, nanobody binding to an endogenous target protein could competitively inhibit the target protein's normal function, opening the door to reversible, specific loss-of-function control. This is particularly intriguing, as most existing optogenetic tools regulate binding between two engineered domains, leaving endogenous processes unaffected. OptoNBs also have high potential for use as light-sensitive reagents outside of cells. Light-switchable binders could in principle be used to reversibly neutralize ligands or cell surface receptors on cells, tissues, or organisms that have not been genetically modified 31 ; they could also enable separation of target proteins from complex mixtures without a need for affinity tags that may interfere with the target protein's function 42 .
Importantly, we find that the existing mCherry-targeting LaM8 OptoNBs are already viable optogenetic tools for intracellular applications. LaM8-AK74 exhibits photoswitchable mCherry binding that is comparable to other high-quality optogenetic tools, with low basal binding in the dark and large-scale protein translocation to the membrane upon illumination. We also demonstrate that this localization change can be harnessed for regulating intracellular processes How might OptoNB function be further improved? One possible route to improvement could be to improve the allosteric coupling between the LOV domain's insertion site and nanobody's target-binding surface. A larger change in binding affinity may thus be achieved by testing additional nanobody insertion sites using the shortened LOV domain sequence or screening additional LOV domain variants with tighter dark-state binding 43 . We also note the apparent discrepancy between the large localization change observed in cells (Figure 2C ) and the in vitro binding assay ( Table 1) . It is thus possible that OptoNBs respond differently in these different biochemical environments. For example, nanobodies contain a disulfide bond that may be differentially formed depending on the reducing environment and might alter the nanobody's sensitivity to allosteric control. OptoNBs thus hold considerable promise for delivering programmable, light-controlled binding for broad range of applications inside and outside cells. (imaging and blue light excitation) was used to image the beads as previously described for the cell imaging, except for the use of a 20X air objective lens for the beads.
Materials and Methods
Bio-layer interferometry measurements of binding kinetics:
Measurements for the on rates (kon), off rates (koff), and affinity constants (KD) for LaM8, LaM8 AK74, and LaM8 GG15 nanobodies were performed on Octet RED96e instruments (ForteBio). Ni-NTA sensors (ForteBio) were first equilibrated in 50 mM Tris pH 8.0, 150 mM NaCl buffer for 10 min prior the measurement. Clear 96-well plates were used for the measurements and wells were filled with 200 μL of buffer or sample. During the experimental run the sensors were first immersed in a buffer to record the baseline, then switched to load the His-tagged nanobody onto the sensor and back into the buffer to remove unbound nanobody. To measure the association rate the sensors were subsequently moved into a well with 8 different concentrations of tagless mCherry including a control with 0 mM mCherry. To measure the koff the sensors were then moved into wells with a buffer and the dissociation rate was recorded. In order to measure binding kinetics 
